← Back to headlines
Nuvation Bio and Eisai Receive EMA Validation for Taletrectinib
Nuvation Bio Inc. (NUVB) and Eisai have received EMA (European Medicines Agency) validation for their drug Taletrectinib, moving it forward in the regulatory process.
1 Apr, 11:07 — 1 Apr, 11:07
Sources
Showing 1 of 1 sources
Related Stories
Church and NGOs Oppose Privatization of Philippine Hydro Plants
just now
Philippine Official Warns Against Fuel Rationing Talks to Prevent Hoarding
just now
DA: PH has fertilizer supply, alternatives amid Middle East tension
just now
Instead of fare hike, Kidapawan grants trike drivers P1,000 fuel subsidy
just now